These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 15950727)

  • 1. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
    Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
    J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
    Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA
    Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
    Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
    J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
    Mueller BM; Romerdahl CA; Gillies SD; Reisfeld RA
    J Immunol; 1990 Feb; 144(4):1382-6. PubMed ID: 2303711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
    Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
    PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.
    Fest S; Huebener N; Weixler S; Bleeke M; Zeng Y; Strandsby A; Volkmer-Engert R; Landgraf C; Gaedicke G; Riemer AB; Michalsky E; Jaeger IS; Preissner R; Förster-Wald E; Jensen-Jarolim E; Lode HN
    Cancer Res; 2006 Nov; 66(21):10567-75. PubMed ID: 17079481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen.
    Förster-Waldl E; Riemer AB; Dehof AK; Neumann D; Brämswig K; Boltz-Nitulescu G; Pehamberger H; Zielinski CC; Scheiner O; Pollak A; Lode H; Jensen-Jarolim E
    Mol Immunol; 2005 Feb; 42(3):319-25. PubMed ID: 15589320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
    Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN
    PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
    Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
    Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
    Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
    Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.